H-36731: Finasteride in Management of Elevated Red Blood Cells

• ClinicalTrials.gov Identifier: NCT02548117
• Recruitment Status: Withdrawn
• First Posted: September 14, 2015
• Last Update Posted: December 16, 2019
• Sponsor: Baylor College of Medicine
• Information provided by (Responsible Party): Larry I. Lipshultz, Baylor College of Medicine

Study Description

Brief Summary:

Hypogonadism (low testosterone) is becoming an increasingly recognized problem that affects numerous men in the United States. Symptoms may be always feeling tired, lower sex drive, and loss of muscle mass. Treatment typically involves testosterone in either injections or a topical gel form.

However, administration of testosterone is not without side effects of its own. Testosterone supplementation therapy is known to cause a variety of side effects including high blood pressure and high lipids (fats) and an increased proportion of red blood cells. Side effects of increased red blood cells can include an increased risk of developing a blood clot.

The increase in the red blood cells is related to dihydrotestosterone (DHT - a male sex hormone) activity. It is normal for the testosterone to become DHT. DHT has various effects on the body including growth of the prostate gland, baldness, and others and DHT levels have been linked to elevated red blood cell counts in men on testosterone.

Finasteride is an FDA approved medication used in the treatment of benign prostatic hypertrophy (BPH) in men with enlarged prostate to improve symptoms and to reduce the risk of the need for surgery. Finasteride may prevent elevations in or reduce elevated red blood cell levels in men on testosterone.

Condition or disease	Intervention/treatment	Phase
ERYTHROCYTOSIS	Drug: Finasteride	Phase 3

Detailed Description:

Hypogonadism is becoming an increasingly recognized clinical syndrome affecting millions of men in the United States and globally, and is characterized by symptoms including chronic fatigue, decreased libido and muscle mass, and low serum testosterone level. Treatment of hypogonadism in men typically involves treatment with exogenous testosterone.

However, exogenous testosterone therapy is not without risks, and can cause numerous side effects including high blood pressure, hyperlipidemia, and erythrocytosis, or elevated hematocrit. Adverse effects of erythrocytosis can include an increased risk of developing thromboembolism, and treatment of erythrocytosis involves therapeutic phlebotomy and testosterone dose adjustment, which can decrease the symptomatic benefits of testosterone therapy.

Aghazadeh et al.found that erythrocytosis occurring during testosterone therapy may be related to dihydrotestosterone (DHT) levels. As part of normal physiology, testosterone is converted to DHT via 5-alpha reductase (5AR). DHT is associated with various effects on the body, including stimulation of prostate growth, male pattern baldness, and others. Currently, finasteride, a 5-alpha reductase inhibitor (5ARI), is available as an FDA-approved drug used to treat DHT-related prostate growth and to prevent DHT-related baldness.

Given the positive association between DHT and the increased hematocrit seen in men being treated for hypogonadism with exogenous testosterone, finasteride's effects in preventing the synthesis of DHT may improve or even prevent erythrocytosis in men on testosterone.

The study will be a prospective randomized controlled trial of patients on injectable testosterone therapy. Subjects will be evenly distributed between the control and treatment groups. The treatment groups will receive finasteride and the control groups will not. All subjects will then be followed with blood tests to determine if there are any changes in their hematocrit, testosterone, DHT, and other blood test values.

An interim data analysis will be performed after approximately 150 men (75 treatment and 75 control) are accrued into the study and followed for at least 1 year. Rates of hematocrit elevation and erythrocytosis will be evaluated in finasteride treated and untreated men to determine whether finasteride is having an impact on erythrocytosis rates and whether any unanticipated adverse effects are occurring. Secondary outcomes, including effects on erythropoietin and hepcidin levels, will also be evaluated. Study accrual will continue if there is evidence that finasteride may decrease the incidence of erythrocytosis. The study will be stopped if unacceptable adverse events are identified or if there is no evidence suggesting that finasteride mitigates the risk of erythrocytosis.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 0 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: H-36371: Finasteride as a Method of Managing Testosterone-Induced Erythrocytosis
• Study Start Date: February 2016
• Actual Primary Completion Date: February 2016
• Actual Study Completion Date: February 2016

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Finasteride; ARM 1 subjects will receive finasteride 5 mg orally daily.	Drug: Finasteride; Subjects will take 5 mg finasteride orally every day for about 2 years.; Other Name: Proscar
No Intervention: No Treatment; The ARM 2 (control group) will not receive any study treatment.

Outcome Measures

Primary Outcome Measures :

1. Evaluation of serum hemoglobin parameters as a function of serum DHT levels [ Time Frame: Approximately 2 years ]
   Comparison between the two ARMS will be done to determine if administration of finasteride may prevent elevations in or reduce levels of hemoglobin/hematocrit.
2. Evaluation of serum hematocrit parameters as a function of serum DHT levels [ Time Frame: Approximately 2 years ]
   Comparison between the two ARMS will be done to determine if administration of finasteride may prevent elevations in or reduce levels of hemoglobin/hematocrit.
3. Evaluation of serum hormone parameters as a function of serum DHT levels [ Time Frame: Approximately 2 years ]
   Comparison between the two ARMS will be done to determine if administration of finasteride may prevent elevations in or reduce levels of hemoglobin/hematocrit.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Adult males 18 years of age or older
• Currently is being treated for hypogonadism with testosterone therapy using injectable testosterone.
• Must not have erythrocytosis (defined as a hematocrit of 52% or higher) attributable to other medication or medical condition
• Agree not to initiate any other treatment for erectile dysfunction (ED), including herbal and over- the-counter (OTC) medications, for the duration of the study.
• Must not already be taking finasteride or other 5-alpha reductase inhibitor

Exclusion Criteria:

• Men not currently using testosterone supplementation therapy or men on non-injectable testosterone therapy
• Prior history of anabolic steroid use, but have not used for at least 6 months
• Prior history of testosterone use, but have not used for at least 6 months
• Men who are already taking finasteride
• Untreated or inadequately treated hypothyroidism
• Significant history of allergy and/or sensitivity to the drug products or excipients, including sensitivity to testosterone and/or finasteride
• Current use of any medications, herbal, and/or nutritional supplements that can interfere with testosterone level
• Currently receiving treatment with cancer chemotherapy or anti-androgens
• Any contraindication to testosterone therapy or finasteride
• History of luteinizing hormone-releasing hormone antagonist or agonist treatment
• History of clomiphene treatment in 6 months prior to Visit 1

Contacts and Locations

Locations

United States, Texas

Baylor College of Medicine

Houston, Texas, United States, 77030

Sponsors and Collaborators

Baylor College of Medicine

Investigators

• Principal Investigator: Larry I. Lipshultz, MD; Baylor College of Medicine

More Information

• Responsible Party: Larry I. Lipshultz, Professor of Urology, Baylor College of Medicine
• ClinicalTrials.gov Identifier: NCT02548117
• Other Study ID Numbers: 03-15-40-10
• First Posted: September 14, 2015
• Last Update Posted: December 16, 2019
• Last Verified: December 2019

Keywords provided by Larry I. Lipshultz, Baylor College of Medicine:

Testosterone therapy; erythrocytosis; finasteride

Additional relevant MeSH terms:

Polycythemia; Hematologic Diseases; Finasteride; Testosterone; Androgens; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; 5-alpha Reductase Inhibitors; Steroid Synthesis Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Hormone Antagonists; Urological Agents